Pasar al contenido principal

Análisis de la calidad del reservorio del VIH-1 en controladores de élite persistentes y en personas bajo cART a largo plazo, asociación con parámetros inmunitarios.

PI22/01796

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i en Salud
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA
Centro realización FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size

  • Jimenez-Leon, Maria Reyes|||0000-0003-2723-319X
  • Gasca-Capote, Carmen|||0000-0002-7211-8599
  • Roca-Oporto, Cristina|||0000-0003-0079-5491
  • Espinosa, Nuria|||0000-0003-2249-2352
  • Sobrino, Salvador
  • Fontillon-Alberdi, Maria|||0000-0003-4031-8067
  • Gao, Ce
  • Roseto, Isabelle
  • Gladkov, Gregory
  • Rivas-Jeremias, Inmaculada
  • Neukam, Karin
  • Sánchez Hernández, José Germán
  • Rigo Bonnin, Raül|||0000-0001-5511-074X
  • Cervera-Barajas, Antonio J.
  • Mesones, Rosario
  • García, Federico
  • Alvarez-Rios, Ana Isabel
  • Bachiller, Sara
  • Vitalle, Joana
  • Perez-Gomez, Alberto
  • Camacho-Sojo, María Inés
  • Gallego, Isabel
  • Brander, Christian|||0000-0002-0548-5778
  • McGowan, Ian
  • Mothe, Beatriz|||0000-0001-9975-407X
  • Viciana, Pompeyo|||0000-0001-5606-0166
  • Yu, Xu
  • Lichterfeld, Mathias
  • López Cortés, Luis Fernando|||0000-0002-3804-3458
  • Ruiz-Mateos, Ezequiel|||0000-0001-6747-7813
BACKGROUND. We evaluated the safety and viral rebound, after analytical treatment interruption (ATI), of vedolizumab and ART in recent HIV-1 infection. We used this model to analyze the effect of α4β7 on the HIV-1 reservoir size. METHODS. Participants started ART with monthly vedolizumab infusions, and ATI was performed at week 24. Biopsies were obtained from ileum and cecum at baseline and week 24. Vedolizumab levels, HIV-1 reservoir, flow cytometry, and cell-sorting and antibody competition experiments were assayed. RESULTS. Vedolizumab was safe and well tolerated. No participant achieved undetectable viremia off ART 24 weeks after ATI. Only a modest effect on the time to achieve more than 1,000 HIV-1 RNA copies/mL and the proportion of participants off ART was observed, being higher in the vedolizumab group compared with historical controls. Just before ATI, α4β7 expression was associated with HIV-1 DNA and RNA in peripheral blood and with PD1 and TIGIT levels. Importantly, a complete blocking of α4β7 was observed on peripheral CD4 T cells but not in gut (ileum and cecum), where α4β7 blockade and vedolizumab levels were inversely associated with HIV-1 DNA. CONCLUSION. Our findings support α4β7 as an important determinant in HIV-1 reservoir size, suggesting the complete α4β7 blockade in tissue as a promising tool for HIV-cure combination strategies. TRIAL REGISTRATION. ClinicalTrials.gov NCT03577782. FUNDING. This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, "a way to make Europe," research contracts FI17/00186 and FI19/00083 and research projects PI18/01532, PI19/01127, PI22/01796), Conserjería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía (research projects P20/00906), the Red Temática de Investigación Cooperativa en SIDA (RD16/0025/0020), and the Spanish National Research Council.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Persistent elite controllers as the key model to identify permanent HIV remission

  • Gasca-Capote, Carmen
  • Ruiz-Mateos, Ezequiel
[Purpose of review] To summarize the heterogeneity in the elite controllers population with the aim to identify a compatible profile with a persistent HIV remission, making distinction between persistent elite controllers, people with HIV (PWHIV) who permanently maintain virological control in the absence of antiretroviral treatment (ART), and transient elite controllers, PWHIV who eventually lose virological control. For this purpose, it is important to consider the mechanisms and biomarkers that have previously been associated with the maintenance and loss of the natural virological control., [Recent findings] Transient elite controllers, before losing virological control, exhibit a distinct metabolomic, proteomic, microRNAs (miRNA), immunological and virological profile compared to persistent elite controllers. In addition to a reduced and less polyfunctional HIV-specific T-cell response, transient elite controllers show a greater proportion of intact proviruses integrated into genic regions. In contrast, persistent elite controllers display a privileged HIV-1 reservoir profile with absence of detected intact proviruses or low proportion of clonal intact proviruses preferentially integrated into genomic features associated with HIV-1 transcriptional repression., [Summary] According to previous studies, the comprehensive characterization of persistent elite controllers might be crucial to identify other PWHIV with this distinct profile as spontaneously cured., This work was supported by the Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional, FEDER, “a way to make Europe”, research contracts FI19/00083 and MV20/00057 to C.G.C. and research projects PI19/01127 and PI22/01796 to E.R.M.) and Gilead Fellowships (GLD22/00147 to E.R.M.). E.R.M. was granted by the Spanish National Research Council (CSIC)., Peer reviewed